Charlotte M Proby

List of Publications by Year
in descending order

101 papers	5,929 citations	66343 42 h-index	76900 74 g-index
102 all docs	102 docs citations	102 times ranked	6853 citing authors

#	Article	IF	Citations
1	A summary of the updated report on the incidence and epidemiological trends of keratinocyte cancers in the UK 2013â€“2018. British Journal of Dermatology, 2022, 186, 367-369.	1.5	6
2	Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments). British Journal of Dermatology, 2022, 187, 324-337.	1.5	15
3	A 10â€year review of surgical management of dermatofibrosarcoma protuberans*. British Journal of Dermatology, 2021, 184, 731-739.	1.5	22
4	British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020*. British Journal of Dermatology, 2021, 184, 401-414.	1.5	63
5	The burden of cutaneous disease in solid organ transplant recipients of color. American Journal of Transplantation, 2021, 21, 1215-1226.	4.7	13
6	Prediction of sentinel node status using melanoma eâ€prognostic tools. Clinical and Experimental Dermatology, 2021, 46, 743-744.	1.3	2
7	The impact of the COVIDâ€19 pandemic on skin cancer incidence and treatment in England, 2020. British Journal of Dermatology, 2021, 185, 460-462.	1.5	15
8	Clinically relevant aberrant Filip1l DNA methylation detected in a murine model of cutaneous squamous cell carcinoma. EBioMedicine, 2021, 67, 103383.	6.1	4
9	The Genomic Landscape of Actinic Keratosis. Journal of Investigative Dermatology, 2021, 141, 1664-1674.e7.	0.7	34
10	An updated report on the incidence and epidemiological trends of keratinocyte cancers in the United Kingdom 2013â€“2018. Skin Health and Disease, 2021, 1, e61.	1.5	12
11	Consensus-Based Recommendations on the Prevention of Squamous Cell Carcinoma in Solid Organ Transplant Recipients. JAMA Dermatology, 2021, 157, 1219.	4.1	24
12	Robust Selective Classification of Skin Lesions with Asymmetric Costs. Lecture Notes in Computer Science, 2021, , 112-121.	1.3	1
13	Achieving integrated self-directed Cancer aftercare (ASICA) for melanoma: how a digital intervention to support total skin self-examination was used by people treated for cutaneous melanoma. BMC Cancer, 2021, 21, 1217.	2.6	6
14	The Identification of Potential TherapeuticÂTargets for Cutaneous SquamousÂCell Carcinoma. Journal of Investigative Dermatology, 2020, 140, 1154-1165.e5.	0.7	10
15	Sulfoxythiocarbamate S-4 inhibits HSP90 in human cutaneous squamous cell carcinoma cells. European Journal of Pharmacology, 2020, 889, 173609.	3.5	2
16	Feasibility of a trial to evaluate nicotinamide for chemoprevention of skin cancers in organ transplant recipients in the UK. British Journal of Dermatology, 2020, 183, 394-396.	1.5	3
17	A feasibility study of microwave therapy for precancerous actinic keratosis. British Journal of Dermatology, 2020, 183, 222-230.	1.5	9
18	Skin cancer burden in lung transplant recipients: we need to do better!. British Journal of Dermatology, 2020, 183, 416-417.	1.5	0

#	Article	IF	Citations
19	Patient preferences for topical treatment of actinic keratoses: a discreteâ€choice experiment. British Journal of Dermatology, 2019, 180, 902-909.	1.5	14
20	A Unique Panel of Patient-Derived Cutaneous Squamous Cell Carcinoma Cell Lines Provides a Preclinical Pathway for Therapeutic Testing. International Journal of Molecular Sciences, 2019, 20, 3428.	4.1	14
21	Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study. Journal of the American Academy of Dermatology, 2019, 81, 448-455.	1.2	31
22	Achieving Self-Directed Integrated Cancer Aftercare (ASICA) in melanoma: protocol for a randomised patient-focused pilot trial of delivering the ASICA intervention as a means to earlier detection of recurrent and second primary melanoma. Trials, 2019, 20, 318.	1.6	11
23	Azathioprine: friend or foe?. British Journal of Dermatology, 2019, 180, 961-963.	1.5	5
24	Collagen Prolyl Hydroxylases Are Bifunctional Growth Regulators in Melanoma. Journal of Investigative Dermatology, 2019, 139, 1118-1126.	0.7	29
25	Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013â€“15: a cohort study. British Journal of Dermatology, 2019, 181, 474-482.	1.5	106
26	Investigation into the use of histone deacetylase inhibitor MS-275 as a topical agent for the prevention and treatment of cutaneous squamous cell carcinoma in an SKH-1 hairless mouse model. PLoS ONE, 2019, 14, e0213095.	2.5	10
27	Treatment approaches in immunosuppressed patients with advanced <scp>cutaneous squamous cell carcinoma</scp>. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 57-60.	2.4	17
28	Completion lymphadenectomy should not necessarily be recommended after a positive sentinel lymph node biopsy. Clinical and Experimental Dermatology, 2019, 44, 79-80.	1.3	1
29	Keratinocyte Carcinomas: Current Concepts and Future Research Priorities. Clinical Cancer Research, 2019, 25, 2379-2391.	7.0	91
30	The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention. Oncogene, 2019, 38, 2320-2336.	5.9	32
31	Nationwide Incidence of Metastatic Cutaneous Squamous Cell Carcinoma in England. JAMA Dermatology, 2019, 155, 298.	4.1	110
32	Aggressive Squamous Cell Carcinoma in Organ Transplant Recipients. JAMA Dermatology, 2019, 155, 66.	4.1	56
33	Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nature Communications, 2018, 9, 53.	12.8	175
34	Unraveling the interplay between senescent dermal fibroblasts and cutaneous squamous cell carcinoma cell lines at different stages of tumorigenesis. International Journal of Biochemistry and Cell Biology, 2018, 98, 113-126.	2.8	7
35	The Microevolution and Epidemiology of Staphylococcus aureus Colonization during Atopic Eczema Disease Flare. Journal of Investigative Dermatology, 2018, 138, 336-343.	0.7	46
36	Human papillomavirus and posttransplantation cutaneous squamous cell carcinoma: A multicenter, prospective cohort study. American Journal of Transplantation, 2018, 18, 1220-1230.	4.7	62

#	Article	IF	Citations
37	Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity. Oncotarget, 2018, 9, 20265-20281.	1.8	21
38	Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma. JCI Insight, 2018, 3, .	5.0	27
39	The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature. Nature Communications, 2018, 9, 3667.	12.8	208
40	The Role of Human Papillomaviruses and Polyomaviruses in BRAF-Inhibitor Induced Cutaneous Squamous Cell Carcinoma and Benign Squamoproliferative Lesions. Frontiers in Microbiology, 2018, 9, 1806.	3.5	24
41	Epithelial damage and tissue Î³Î´ T cells promote a unique tumor-protective IgE response. Nature Immunology, 2018, 19, 859-870.	14.5	92
42	The widespread use of topical antimicrobials enriches for resistance inStaphylococcus aureusisolated from patients with atopic dermatitis. British Journal of Dermatology, 2018, 179, 951-958.	1.5	33
43	Reduced SMAD2/3 activation independently predicts increased depth of human cutaneous squamous cell carcinoma. Oncotarget, 2018, 9, 14552-14566.	1.8	9
44	Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity. Oncotarget, 2018, 9, 23029-23046.	1.8	18
45	Painful skin lesions and squamous cell carcinoma predict overall mortality risk in organ transplant recipients: a cohort study. British Journal of Dermatology, 2017, 176, 1179-1186.	1.5	5
46	Whole-Exome Sequencing Validates a Preclinical Mouse Model for the Prevention and Treatment of Cutaneous Squamous Cell Carcinoma. Cancer Prevention Research, 2017, 10, 67-75.	1.5	17
47	Patients with low-risk cutaneous squamous cell carcinoma do not require extended out-patient follow-up. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2017, 70, 852-855.	1.0	5
48	The pathogenesis of cutaneous squamous cell carcinoma in organ transplant recipients. British Journal of Dermatology, 2017, 177, 1217-1224.	1.5	58
49	Organ transplantation and cutaneous squamous cell carcinoma: progress, pitfalls and priorities in immunosuppressionâ€associated keratinocyte carcinoma. British Journal of Dermatology, 2017, 177, 1150-1151.	1.5	9
50	Genomic analysis of atypical fibroxanthoma. PLoS ONE, 2017, 12, e0188272.	2.5	23
51	The Promise of Genomics and the Development of Targeted Therapies for Cutaneous Squamous Cell Carcinoma. Acta Dermato-Venereologica, 2016, 96, 3-16.	1.3	46
52	MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2016, 136, 1920-1924.	0.7	12
53	Inactivation of TGFÎ² receptors in stem cells drives cutaneous squamous cell carcinoma. Nature Communications, 2016, 7, 12493.	12.8	81
54	Nrf2 Activation Protects against Solar-Simulated Ultraviolet Radiation in Mice and Humans. Cancer Prevention Research, 2015, 8, 475-486.	1.5	94

#	Article	IF	Citations
55	MicroRNA-135b Regulates Leucine Zipper Tumor Suppressor 1 in Cutaneous Squamous Cell Carcinoma. PLoS ONE, 2015, 10, e0125412.	2.5	23
56	Key differences identified between actinic keratosis and cutaneous squamous cell carcinoma by transcriptome profiling. British Journal of Cancer, 2014, 110, 520-529.	6.4	94
57	Epidermal Growth Factor Receptor substrate 8 (Eps8) controls Src/FAK-dependent phenotypes in squamous carcinoma cells. Journal of Cell Science, 2014, 127, 5303-16.	2.0	21
58	NOTCH1 Mutations Occur Early during Cutaneous Squamous Cell Carcinogenesis. Journal of Investigative Dermatology, 2014, 134, 2630-2638.	0.7	287
59	Longitudinal study of seroprevalence and serostability of 34 human papillomavirus types in European organ transplant recipients. Virology, 2013, 436, 91-99.	2.4	12
60	Pattern of sensitivity of progressive cutaneous squamous cell carcinoma cells to UVB and oxidative stress-induced cell death. Photochemical and Photobiological Sciences, 2013, 12, 104-110.	2.9	3
61	A Surveillance Model for Skin Cancer in Organ Transplant Recipients: A 22-Year Prospective Study in an Ethnically Diverse Population. American Journal of Transplantation, 2013, 13, 119-129.	4.7	122
62	Methylated Tissue Factor Pathway Inhibitor 2 (TFPI2) DNA in Serum Is a Biomarker of Metastatic Melanoma. Journal of Investigative Dermatology, 2013, 133, 1278-1285.	0.7	44
63	Two-Year Randomized Controlled Prospective Trial Converting Treatment of Stable Renal Transplant Recipients With Cutaneous Invasive Squamous Cell Carcinomas to Sirolimus. Journal of Clinical Oncology, 2013, 31, 1317-1323.	1.6	133
64	Factors associated with the seroprevalence of 26 cutaneous and two genital human papillomavirus types in organ transplant patients. Journal of General Virology, 2012, 93, 165-174.	2.9	8
65	Population-Based Estimates of the Occurrence of Multiple vs First Primary Basal Cell Carcinomas in 4 European Regions. Archives of Dermatology, 2012, 148, 347.	1.4	38
66	Basal cell carcinomas without histological confirmation and their treatment: an audit in four European regions. British Journal of Dermatology, 2012, 167, 22-28.	1.5	17
67	Risk factors for actinic keratosis in eight European centres: a case-control study. British Journal of Dermatology, 2012, 167, 36-42.	1.5	86
68	Skin Cancer Prevention: Recent Evidence from Randomized Controlled Trials. Current Dermatology Reports, 2012, 1, 123-130.	2.1	7
69	Autophagy Inhibitor Chloroquine Enhanced the Cell Death Inducing Effect of the Flavonoid Luteolin in Metastatic Squamous Cell Carcinoma Cells. PLoS ONE, 2012, 7, e48264.	2.5	77
70	The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro. Journal of Pathology, 2012, 226, 451-462.	4.5	36
71	Wnt5a Is Strongly Expressed at the Leading Edge in Non-Melanoma Skin Cancer, Forming Active Gradients, while Canonical Wnt Signalling Is Repressed. PLoS ONE, 2012, 7, e31827.	2.5	53
72	Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma. Oncogene, 2011, 30, 4666-4677.	5.9	65

#	Article	IF	Citations
73	A Case-Control Study of Betapapillomavirus Infection and Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients. American Journal of Transplantation, 2011, 11, 1498-1508.	4.7	115
74	Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17761-17766.	7.1	405
75	Concomitant inhibition of AKT and autophagy is required for efficient cisplatinâ€induced apoptosis of metastatic skin carcinoma. International Journal of Cancer, 2010, 127, 2790-2803.	5.1	75
76	Multicenter Study of the Association between Betapapillomavirus Infection and Cutaneous Squamous Cell Carcinoma. Cancer Research, 2010, 70, 9777-9786.	0.9	130
77	The Flavonoid Luteolin Increases the Resistance of Normal, but Not Malignant Keratinocytes, Against UVB-Induced Apoptosis. Journal of Investigative Dermatology, 2010, 130, 2277-2285.	0.7	33
78	Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma. Journal of General Virology, 2009, 90, 1611-1621.	2.9	89
79	Single Nucleotide Polymorphism Array Analysis Defines a Specific Genetic Fingerprint for Well-Differentiated Cutaneous SCCs. Journal of Investigative Dermatology, 2009, 129, 1562-1568.	0.7	40
80	The Epidemiology of Transplant-Associated Keratinocyte Cancers in Different Geographical Regions. Cancer Treatment and Research, 2009, 146, 75-95.	0.5	17
81	PTCH mutations in basal cell carcinomas from azathioprine-treated organ transplant recipients. British Journal of Cancer, 2008, 99, 1276-1284.	6.4	54
82	Î²-Papillomaviruses and psoriasis: an intra-patient comparison of human papillomavirus carriage in skin and hair. British Journal of Dermatology, 2008, 159, 113-119.	1.5	39
83	Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. British Journal of Dermatology, 2007, 157, 25-31.	1.5	149
84	Keratotic Skin Lesions and Other Risk Factors Are Associated with Skin Cancer in Organ-Transplant Recipients: A Caseâ€“Control Study in The Netherlands, United Kingdom, Germany, France, and Italy. Journal of Investigative Dermatology, 2007, 127, 1647-1656.	0.7	137
85	Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. British Journal of Dermatology, 2007, 156, 320-328.	1.5	173
86	Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photoprotection and levels of skin cancer awareness. British Journal of Dermatology, 2006, 155, 916-925.	1.5	93
87	Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours. British Journal of Cancer, 2006, 94, 1446-1451.	6.4	43
88	Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals. British Journal of Dermatology, 2005, 152, 122-129.	1.5	67
89	Human Papillomavirus Gene Expression in Cutaneous Squamous Cell Carcinomas from Immunosuppressed and Immunocompetent Individuals. Journal of Investigative Dermatology, 2005, 125, 98-107.	0.7	87
90	Human Papillomavirus-DNA Loads in Actinic Keratoses Exceed those in Non-Melanoma Skin Cancers. Journal of Investigative Dermatology, 2005, 125, 93-97.	0.7	229

#	Article	IF	Citations
91	Safety and Efficacy of 5% Imiquimod Cream for the Treatment of Skin Dysplasia in High-Risk Renal Transplant Recipients. Archives of Dermatology, 2005, 141, 985-93.	1.4	99
92	Low-Dose Retinoids in the Prevention of Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients. Archives of Dermatology, 2005, 141, 456-64.	1.4	112
93	Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin. British Journal of Dermatology, 2004, 150, 949-957.	1.5	153
94	High frequency and diversity of cutaneous appendageal tumors in organ transplant recipients. Journal of the American Academy of Dermatology, 2003, 48, 401-408.	1.2	77
95	Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. Journal of Medical Virology, 2000, 61, 289-297.	5.0	398
96	Genetic Characterization of a Human Skin Carcinoma Progression Model: from Primary Tumor to Metastasis. Journal of Investigative Dermatology, 2000, 115, 1095-1103.	0.7	47
97	Spontaneous keratinocyte cell lines representing early and advanced stages of malignant transformation of the epidermis. Experimental Dermatology, 2000, 9, 104-117.	2.9	66
98	Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. , 2000, 61, 289.		3
99	Keratin 17 expression as a marker for epithelial transformation in viral warts. American Journal of Pathology, 1993, 143, 1667-78.	3.8	33
100	Adjuvant radiotherapy in patients with highâ€risk cutaneous Squamous Cell Carcinoma After surgery (SCCâ€AFTER): Patient and carer views regarding a proposed clinical trial. Clinical and Experimental Dermatology, 0, , .	1.3	0
101	Clinicopathological characteristics of individuals with coâ€existing melanoma and chronic lymphocytic leukaemia: a multicentre cohort study. Clinical and Experimental Dermatology, 0, , .	1.3	0